Literature DB >> 21703983

Diagnostic microRNAs in myelodysplastic syndrome.

Begum Erdogan1, Crystal Facey, Julianne Qualtieri, Jason Tedesco, Elizabeth Rinker, R Benjamin Isett, John Tobias, Donald A Baldwin, James E Thompson, Martin Carroll, Annette S Kim.   

Abstract

OBJECTIVE: The myelodysplastic syndromes (MDS) are aging-associated disorders characterized by ineffective maturation of hematopoietic elements, which are often diagnostically challenging. This study identifies microRNAs (miRNA) and miRNA targets that might represent diagnostic markers for MDS.
MATERIALS AND METHODS: This study utilized a total of 42 MDS samples and 45 controls. A discovery set of 20 frozen bone marrow mononuclear cell samples (10 MDS, 10 controls) was profiled on a custom Agilent miRNA microarray. Classifier miRNAs were validated in a separate set of 49 paraffin-embedded particle preparations by real-time polymerase chain reaction (24 MDS, 25 controls). Target prediction analysis was compared to a de novo transcriptional profile of MDS derived from the Microarray Innovations in Leukemia study. c-Myb and Sufu were further investigated by immunohistochemical stains on a set of 26 paraffin-embedded samples.
RESULTS: We identified 13 miRNAs of interest from the discovery set, 8 of which proved statistically significant on real-time polymerase chain reaction verification. These eight miRNAs were then examined in an independent real-time polymerase chain reaction validation set. Notably, hsa-miR-378, hsa-miR-632, and hsa-miR-636 demonstrated particularly high discrimination between MDS and normal controls. Target prediction identified potential targets of miRNA regulation that correspond to many of the genes that characterize MDS. Immunohistochemical staining performed on a third validation set confirmed that c-Myb and Sufu are differentially expressed in MDS.
CONCLUSIONS: Our data utilize both discovery and validation sets and two complementary platforms to identify miRNAs associated with MDS. We have analyzed predicted targets and identified c-Myb and Sufu as potential diagnostic markers of MDS.
Copyright © 2011 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703983     DOI: 10.1016/j.exphem.2011.06.002

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  21 in total

1.  MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia.

Authors:  Yan Guo; Stephen A Strickland; Sanjay Mohan; Shaoying Li; Amma Bosompem; Kasey C Vickers; Shilin Zhao; Quanhu Sheng; Annette S Kim
Journal:  Leuk Lymphoma       Date:  2017-01-13

2.  Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Felicitas Thol; Michaela Scherr; Aylin Kirchner; Rabia Shahswar; Karin Battmer; Sofia Kade; Anuhar Chaturvedi; Christian Koenecke; Michael Stadler; Uwe Platzbecker; Christian Thiede; Thomas Schroeder; Guido Kobbe; Gesine Bug; Oliver Ottmann; Wolf-Karsten Hofmann; Nicolaus Kröger; Walter Fiedler; Richard Schlenk; Konstanze Döhner; Hartmut Döhner; Jürgen Krauter; Matthias Eder; Arnold Ganser; Michael Heuser
Journal:  Haematologica       Date:  2014-12-31       Impact factor: 9.941

3.  Methylation of promoters of microRNAs and their host genes in myelodysplastic syndromes.

Authors:  Begum Erdogan; Amma Bosompem; Dunfa Peng; Leng Han; Emily Smith; Mija E Kennedy; Catherine E Alford; Huiyun Wu; Zhongming Zhao; Claudio A Mosse; Wael El-Rifai; Annette S Kim
Journal:  Leuk Lymphoma       Date:  2013-05-15

4.  The Werner syndrome RECQ helicase targets G4 DNA in human cells to modulate transcription.

Authors:  Weiliang Tang; Ana I Robles; Richard P Beyer; Lucas T Gray; Giang H Nguyen; Junko Oshima; Nancy Maizels; Curtis C Harris; Raymond J Monnat
Journal:  Hum Mol Genet       Date:  2016-03-16       Impact factor: 6.150

5.  Expressional changes of genes and miRNA in common megakaryocyte-erythroid progenitors from lower-risk myelodysplastic syndrome.

Authors:  Kazuhiro Maki; Ko Sasaki; Yasunobu Nagata; Fusako Nagasawa; Yuka Nakamura; Seishi Ogawa; Kinuko Mitani
Journal:  Int J Hematol       Date:  2014-07-24       Impact factor: 2.490

Review 6.  Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes.

Authors:  Diamantina Vasilatou; Sotirios G Papageorgiou; George Dimitriadis; Vasiliki Pappa
Journal:  Epigenetics       Date:  2013-05-09       Impact factor: 4.528

Review 7.  The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.

Authors:  Azra Raza; Naomi Galili
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

Review 8.  Implication of microRNAs in the pathogenesis of MDS.

Authors:  Jing Fang; Melinda Varney; Daniel T Starczynowski
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

9.  Micro-RNA-632 downregulates DNAJB6 in breast cancer.

Authors:  Aparna Mitra; Jack W Rostas; Donna L Dyess; Lalita A Shevde; Rajeev S Samant
Journal:  Lab Invest       Date:  2012-06-18       Impact factor: 5.662

Review 10.  Multi-Omics Model Applied to Cancer Genetics.

Authors:  Francesco Pettini; Anna Visibelli; Vittoria Cicaloni; Daniele Iovinelli; Ottavia Spiga
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.